Patent intelligence · US
US 11992531
C3-carbon linked glutarimide degronimers for target protein degradation
C3-carbon linked glutarimide degronimers for target protein degradation
Patent details — US 11992531
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2024
- Expiration
- May 23, 2044
- Applicant
- C4 THERAPEUTICS, INC.
- Claims
- 31
- CPC classes
- A61K, A61K31/45, A61K31/451, A61K31/454
Quick answer
US 11992531 (C3-carbon linked glutarimide degronimers for target protein degradation) is held by C4 THERAPEUTICS, INC.. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- C4 THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 31
- CPC classes
- A61K, A61K31/45, A61K31/451, A61K31/454, A61K31/4545, A61K47/545
More from C4 THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421220
Bicyclic-substituted glutarimide cereblon binders
granted -
US 12371442
Isoindolinone and indazole compounds for the degradation of EGFR
granted -
US 12227504
Spirocyclic compounds
granted -
US 12180225
N/O-linked degrons and degronimers for protein degradation
granted -
US 12157735
Compounds for targeted degradation of BRD9
granted -
US 12091397
Dihydroquinolinones for medical treatment
granted -
US 12076405
Heterocyclic degronimers for target protein degradation
granted -
US 12048747
Substituted piperidine Degronimers for Target Protein degradation
granted
Frequently asked questions
What is US patent 11992531?
US 11992531 (C3-carbon linked glutarimide degronimers for target protein degradation) is held by C4 THERAPEUTICS, INC.. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11992531?
C4 THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 11992531 expire?
Our index shows an expiration date of May 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.